Measurable residual disease in the treatment of chronic lymphocytic leukemia

Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment ; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in sever...

Full description

Saved in:
Bibliographic Details
Published inJournal of Clinical and Experimental Hematopathology Vol. 60; no. 4; pp. 138 - 145
Main Authors Takayoshi Uchiyama, Aki Yokoyama, Sadao Aoki
Format Journal Article
LanguageJapanese
Published The Japanese Society for Lymphoreticular Tissue Research 01.12.2020
Online AccessGet full text

Cover

More Information
Summary:Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment ; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in several clinical trials on CLL using flow cytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO) primers, and high-throughput sequencing. MRD assessment is useful to predict the treatment outcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax. In this review, we discuss major techniques for MRD assessment, data from relevant clinical trials, and the future of MRD assessment in CLL treatment.
ISSN:1346-4280